Biotech firm Novavax said Thursday that its coronavirus vaccine was more than 89% effective in protecting against Covid-19 in its phase three clinical trial conducted in the United Kingdom.
The results were based on 62 confirmed Covid-19 infections among the trial’s 15,000 participants. The company said 56 cases were observed in the placebo group versus 6 cases observed in the group that received its vaccine. That resulted in an estimated vaccine efficacy of 89.3%, it said.
Shares of the company were down more than 14% in after-hours trading.
With the results, the company “has the potential to play an important role in solving this global public health crisis,” Novavax CEO Stanley Erck said in a statement. “We look forward to continuing to work with our partners, collaborators, investigators and regulators around the world to make the vaccine available as quickly as possible.”
This is a developing story. Please check back for updates.
View original post